title: The prevalence of the metabolic syndrome and its impact on the left ventricular systolic function in the patients with non-diabetic first ST elevation myocardial infarction.
abstract: OBJECTIVE
  Metabolic syndrome (MS) is common among the patients with myocardial infarction. The degree of the left ventricular systolic dysfunction is shown to be associated with poor prognosis after myocardial infarction. The aim of this study was to evaluate the prevalence of MS and its impact on the left ventricular systolic function in non-diabetic patients suffering first ST elevation myocardial infarction (STEMI).
  
  
  METHODS
  This study was conducted prospectively in three centers. We included patients presenting with non-diabetic first acute STEMI. The systolic functions of the left ventricle were assessed through the ejection fraction, the wall motion score index (WMSI) and tissue Doppler myocardial S wave velocities. The diagnosis of MS was done based on the Adult Treatment Panel III clinical definition of the MS.
  
  
  RESULTS
  Among the 240 patients, 90 patients (37.5%) had MS but 150 patients (62.5%) were free of the MS. The patients in the MS group were older and the prevalence was higher among the females. Mean myocardial S wave velocities were significantly lower in the patients with the MS in comparison to the patients without the MS (6.70 +/- 1.68 vs. 7.39 +/- 1.64; p < 0.01). LVEF and WMSI were similar in two groups.
  
  
  CONCLUSIONS
  MS was highly common in nondiabetic patients with acute STEMI and left ventricular systolic function were more severely impaired in these patients. Our observations suggest that more severely impaired left ventricular systolic function after acute STEMI may contribute to the higher morbidity and mortality seen in the patients with MS after acute STEMI.
authors.affiliation: Department of Cardiology, Gazi University School of Medicine, Ankara, Turkey. drhyazici@gmail.com
authors.forename: H U
authors.initials: HU
authors.lastname: Yazici
authors.forename: F
authors.initials: F
authors.lastname: Poyraz
authors.forename: M
authors.initials: M
authors.lastname: Turfan
authors.forename: N
authors.initials: N
authors.lastname: Sen
authors.forename: Y
authors.initials: Y
authors.lastname: Tavil
authors.forename: M
authors.initials: M
authors.lastname: Tulmac
authors.forename: M A
authors.initials: MA
authors.lastname: Vatankulu
authors.forename: N
authors.initials: N
authors.lastname: Aygül
authors.forename: I
authors.initials: I
authors.lastname: Ozdoğru
authors.forename: A
authors.initials: A
authors.lastname: Abaci
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000453:epidemiology* / Q000503:physiopathology*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging / Q000503:physiopathology*; D014463:Ultrasonography; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D008055:Lipids